Evidence map›Paper›PMID 42243938›Full record

ArticleJournal of nanobiotechnology2026

Enhancing antitumor immunity in triple-negative breast cancer through reversal of T-cell exhaustion using a CD8-targeted and membrane-camouflaged nanocarrier delivering small interfering RNA against sorting Nexin 9.

Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Shusheng Qiu, Xianing Dong, Zengjun Zhu, Xuanxuan Wu, Jianxin Du, Yanbin Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wei Hu *Department of Breast Surgery, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China.
Qishuai Chen *Department of Breast Surgery, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China.
Yan Ma *Center of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China.
Yang LiuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, China.
Shusheng QiuDepartment of Breast Surgery, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China.
Xianing DongSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, China.
Zengjun ZhuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, China.
Xuanxuan WuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, China.
Jianxin DuCenter of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China.
Yanbin XuDepartment of Breast Surgery, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China. xuyanbin0702@126.com.
Maojin TianDepartment of Critical Care Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China. mjtian@mail.ustc.edu.cn.
Peiqing ZhaoCenter of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, No. 54, Gongqingtuan West Road, Zhangdian District, Zibo, 255036, Shandong Province, China. bzjzzpq@sdu.edu.cn.

Funding

National Natural Science Foundation of China 81972002, 12304241Natural Science Foundation of Shandong Province ZR2020MH329Natural Science Foundation of Shandong Province ZR2024MH175, ZR2023QC168, ZR2025MS1329, ZR2021MC126Shandong Provincial Medical and Health Science and Technology Development Project 202309030858Taishan Young Scholar Foundation of Shandong Province tsqnz20231257
6 · The paper itself

Abstract

T cell exhaustion (Tex) severely limits the efficacy of tumor immunotherapy, yet strategies targeting its upstream regulatory mechanisms remain underexplored. In this study, a targeted nanodelivery system, CD8a-RM-MOF@siSNX9, was developed to preferentially enrich siRNA delivery in CD8

Indexed as

CD8-Positive T-LymphocytesNanoparticlesRNA, Small InterferingSorting NexinsTriple Negative Breast NeoplasmsAnimalsCD8 AntigensCell Line, TumorFemaleHumansMiceMice, Inbred BALB CT-Cell ExhaustionTumor MicroenvironmentCD8 AntigensRNA, Small InterferingSorting NexinsMetal–organic framework nanocarrierRed blood cell membrane camouflagesiRNA deliverySorting Nexin 9T-cell exhaustionTriple-negative breast cancer

Identifiers

PMID42243938
PMCPMC13459423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.